The global distribution and the average annual percentage changes (AAPCs) in age-standardized incidence rates (ASRs, per 100.000) of kidney cancer at the national level. (a ASR of kidney cancer in 2017; b ASR of kidney cancer in 2030; c AAPC of kidney cancer ASR between 1990 and 2017; d AAPC of kidney cancer ASR between 2018 and 2030).
Background: Tumor burden and metastatic disease sites are well-established prognostic factors in many malignancies, including metastatic Renal Cell Carcinoma (mRCC)....
Recently the COVID-19 pandemic became the main global priority; main efforts and health infrastructures have been prioritized in favor of COVID-19 battle and the treatment of benign diseases has been postponed. Renal cell cancer (RCC) patients configure a heterogenous populations: some of them present indolent cases which can safely have postponed their treatments, others present aggressive tumors, deserving immediate care. These scenarios must be properly identified before a tailored therapeutic choice....
Background: To evaluate demographic, clinical and pathological characteristics of small renal masses (SRM) (≤ 4 cm) in a Latin-American population provided by LARCG (Latin-American Renal Cancer Group) and analyze predictors of survival, recurrence and metastasis....
Aim: Examine outcomes in sunitinib-treated patients by International Metastatic RCC Database Consortium (IMDC) or Memorial Sloan-Kettering Cancer Center (MSKCC) risk factors. ...
The LARCG (Latin American Renal Cancer Group) is a group of scientific and educational, multicentric, multidisciplinary and independent. It is not for profit, and the term of operation is indeterminate. It consists of Urologists, Pathologists and Oncologists, as well as professionals and researchers related to the field of health, belonging to Hospitals in Latin America, Spain and the United States.
Un orgullo y honor compartir esta Sesión Plenaria @CAU_URO con @StenioZequi @DiegoAbreuC1 @DrFRodriguezCov @autran_anamaria #LARCG # SomosCAU@ @siupurol ✍️🇧🇷, 🇺🇾 🇲🇽 🇪🇸 👇👇 https://twitter.com/drfrodriguezcov/status/1420231197653979136
Un honor poder compartir foro con excelentes colegas de @CAU_URO para comentar casos de #CáncerRenal
@StenioZequi @DiegoAbreuC1 @autran_anamaria https://twitter.com/CAU_URO/status/1420227816109510657
#ASCO21 @ASCO Plenary #LBA5 : Keynote-564 trial results just out 👉https://bit.ly/3g4mQ6Q ,in patients with high risk resected #kidneycancer: Pembrolizumab significantly improves disease free survival. Practice changing data Congrats @DrChoueiri @tompowles1 @OncoAlert
3
